IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

Blood

Volumn 128, Issue 23, 2016, Pages 2683-2693

  Ågerstam, Helena ^a   Hansen, Nils ^a   Von Palffy, Sofia ^a   Sanden, Carl ^a   Reckzeh, Kristian ^a   Karlsson, Christine ^a   Lilljebjörn, Henrik ^a   Landberg, Niklas ^a   Askmyr, Maria ^a   Högberg, Carl ^a   Rissler, Marianne ^a   Porkka, Kimmo ^b   Wadenvik, Hans ^c   Mustjoki, Satu ^b   Richter, Johan ^d   Järås, Marcus ^a   Fioretos, Thoas ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BREAKPOINT CLUSTER REGION PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN RECEPTOR; PROTEIN KINASE B; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; IL1RAP PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL KILLING; CELL PHAGOCYTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EFFECTOR CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LEUKOCYTE COUNT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN TARGETING; RNA SEQUENCE; SIGNAL TRANSDUCTION; SPLEEN WEIGHT; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; DRUG SCREENING; FEMALE; KNOCKOUT MOUSE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85015673060     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-679985     Document Type: Article

References (39)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-183.
3. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013; 122(4):515-522.
4. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424-430.
5. Holyoake TL, Helgason GV. Do we need more drugs for chronic myeloid leukemia? Immunol Rev. 2015;263(1):106-123.
6. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565-5572.
7. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
8. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501-1510.
9. Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428-442.
10. Hehlmann R. How I treat CML blast crisis. Blood. 2012;120(4):737-747.
11. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
12. Drube S, Heink S, Walter S, et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood. 2010;115(19): 3899-3906.
13. Cullinan EB, Kwee L, Nunes P, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol. 1998;161(10):5614-5620.
14. Jära°s M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010; 107(37):16280-16285.
15. Askmyr M, Ägerstam H, Hansen N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013; 121(18):3709-3713.
16. Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120(6): 1290-1298.
17. Agerstam H, Karlsson C, Hansen N, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci USA. 2015; 112(34):10786-10791.
18. Landberg N, Hansen N, Askmyr M, et al. IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. Leukemia. 2016;30(1): 255-258.
19. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3(105):CM1.
20. Cahill CM, Rogers JT. Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem. 2008;283(38): 25900-25912.
21. Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD341 cells. Blood. 1998;91(2): 630-640.
22. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia. 2005; 19(3):435-441.
23. O'Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242-2249.
24. Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667.
25. Tanizaki R, Nomura Y, Miyata Y, et al. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/-mice. Cancer Sci. 2010;101(3): 631-638.
26. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287.
27. Zhang B, Ho YW, Huang Q, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4):577-592.
28. Welner RS, Amabile G, Bararia D, et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell. 2015;27(5):671-681.
29. Estrov Z, Kurzrock R, Wetzler M, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991;78(6):1476-1484.
30. Zhang B, Chu S, Agarwal P, et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood. 2016;128(23):2671-2682.
31. Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma. 2012;53(6): 1084-1089.
32. Mustjoki S, Auvinen K, Kreutzman A, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27(4): 914-924.
33. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85(5):387-398.
34. Nievergall E, Ramshaw HS, Yong ASM, et al. Monoclonal antibody targeting of IL-3 receptor a with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123(8):1218-1228.
35. Florian S, Sonneck K, Hauswirth AW, et al. Detection of molecular targets on the surface of CD341/CD38-stem cells in various myeloid malignancies. Leuk Lymphoma. 2006;47(2): 207-222.
36. Herrmann H, Sadovnik I, Cerny-Reiterer S, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123(25):3951-3962.
37. Kobayashi CI, Takubo K, Kobayashi H, et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood. 2014;123(16):2540-2549.
38. Levescot A, Flamant S, Basbous S, et al. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD341 progenitors from chronic myeloid leukemia patients. Cancer Res. 2014; 74(10):2669-2676.
39. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-652.